MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 2.3%

Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) fell 2.3% on Thursday . The company traded as low as $3.23 and last traded at $3.33. 141,746 shares were traded during mid-day trading, a decline of 65% from the average session volume of 406,809 shares. The stock had previously closed at $3.41.

MAIA Biotechnology Trading Down 2.3 %

The firm has a market capitalization of $72.73 million, a P/E ratio of -2.11 and a beta of 0.46.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its earnings results on Tuesday, May 14th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.13). Analysts forecast that MAIA Biotechnology, Inc. will post -1.25 EPS for the current fiscal year.

Insider Activity

In other MAIA Biotechnology news, Director Ngar Yee Louie acquired 19,665 shares of the company’s stock in a transaction that occurred on Thursday, April 25th. The shares were bought at an average cost of $2.03 per share, with a total value of $39,919.95. Following the completion of the transaction, the director now directly owns 1,167,189 shares of the company’s stock, valued at approximately $2,369,393.67. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 36.98% of the company’s stock.

Institutional Investors Weigh In On MAIA Biotechnology

An institutional investor recently bought a new position in MAIA Biotechnology stock. Virtu Financial LLC acquired a new position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 32,487 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.15% of MAIA Biotechnology as of its most recent SEC filing. Hedge funds and other institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.